The study, which appears online Nov. 29 in The Lancet , builds on previous research that found that the administration of one dose of rectal artesunate by a community health worker to a child with suspected severe malaria significantly reduced the risk of death and permanent disability. In addition to endangering the lives of young children, severe malaria has been associated with a range of developmental deficits.
Rectal artesunate interrupts disease progression by rapidly reducing parasite density, but should be followed by further anti-malarial treatment. Because of this, the team led by Tozan, assistant professor of international health at BUSPH, said: "The success of interventions in the community ultimately depends on whether formal health systems can provide front-line health workers with drugs and other necessary health commodities, regular monitoring and supervision, and linkages to referral systems" for follow-up treatment.
The research team studied a hypothetical cohort of 1,000 newborn babies through five years of age in high malaria transmission settings. The team assessed the costs and cost-effectiveness of artesunate treatment, followed by referral to a health facility, under a variety of intervention uptake and referral compliance scenarios.
The researchers estimated that the full uptake of artesunate treatment and full compliance with referral advice would avert 37 child deaths and 967 disability-adjusted life-years [DALYs] -- a measure which combines years of life lost because of premature death, with years of life lived with disability -- over five years . Across all intervention uptake and referral compliance scenarios, the study reported that the intervention could avert each DALY at a cost of $77 to $1,173.
"Compared with the interventions that target key childhood illnesses in sub-Saharan Africa, pre-referral artesunate treatment is among the most cost-effective, especially if the intervention uptake is moderate or higher," the researchers concluded.
In remote settings in which the start of anti-malarial treatment with injectible drugs is substantially delayed, the 2010 World Health Organization guidelines for treating malaria recommend the use of artesunate or artemisinin suppositories for emergency treatment of patients suspected to have severe malaria, before transfer to a health facility. The use of this intervention remains low, however, in part because of questions about costs and cost-effectiveness.
"This study shows that rectal artesunate is highly cost-effective for saving lives of severely ill patients with malaria living not only at the end of the road, but where there is no road," said Joel G. Breman, MD, senior scientific advisor at the Fogarty International Center of the National Institutes of Health and a co-author on the study.
"There is now full justification to provide community health workers with life-saving rectal artesunate suppositories, training, and instructions for their use and referral follow-up, as part of the essential drug package," he said.
Tozan, who has done extensive research on the social and economic aspects of malaria, said artesunate suppositories are a needed addition to community health workers' arsenals in areas where malaria is a frequent childhood disease.
"Pre-referral artesunate suppositories, if deployed appropriately in communities, address an important treatment gap, due to the weak state of the health-care systems in many malaria-endemic countries," she said.
She said the study's findings "provide strong economic evidence to policy makers who decide which interventions to adopt in resource-constrained areas. Pre-referral artesunate treatment has the potential to get us closer to child-survival targets set by the United Nations and other international agencies."
A 2010 report on the United Nations' Millennium Development Goals notes that "prompt and effective treatment" is critical for preventing life-threatening complications from malaria, particularly in children. The Millennium Development Goals set a target of halting and beginning to reverse the high incidence of malaria by 2015.
The report notes that in the last seven years, many countries have shifted their national drug policies to promote artemisinin-based combination therapies -- a more effective, but also more expensive, treatment course for malaria. Global procurement of these medicines has risen sharply since 2005.
But antimalarial treatment coverage varies widely across African countries, ranging from 67 percent in some areas, to just 1 percent of children under five with fevers receiving any type of antimalarial drug in other regions, the report says. In fact, the proportion of febrile children under five receiving any antimalarial medication exceeded 50 percent in just eight of 37 African countries that provided data from 2005 to 2009.
Half of the world's population is at risk of malaria, with an estimated 243 million cases leading to nearly 863,000 deaths in 2008. Of those, 767,000, or 89 percent, occurred in Africa.
Funding for the new study came from The Disease Control Priorities Project, Fogarty International Center, the US National Institutes of Health; and the Peter Paul Career Development Professorship at Boston University, awarded to Tozan in 2008 to pursue her research into the consequences and treatment of childhood malaria.
Besides Tozan and Breman, other authors of the study include: Eili Y. Klein, Sarah Darley, Rajashree Panicker and Ramanan Laxminarayan of the Center for Disease Dynamics, Economics and Policy.
More information on the study is available by contacting Tozan at email@example.com, or (617) 414-1209.
A link to the study is available here: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61460-2/abstract
Lisa Chedekel | EurekAlert!
The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft
Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung
Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...
Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!
When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...
For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.
Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...
MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.
MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...
Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
20.09.2017 | Life Sciences
20.09.2017 | Power and Electrical Engineering
20.09.2017 | Physics and Astronomy